Charles Schwab’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$698M Buy
1,803,703
+33,208
+2% +$12.3M 0.09% 168
2026
Q1
$518M Buy
1,770,495
+32,773
+2% +$10.8M 0.08% 214
2025
Q4
$609M Buy
1,737,722
+51,502
+3% +$17.4M 0.09% 176
2025
Q3
$545M Sell
1,686,220
-118,325
-7% -$36.8M 0.09% 196
2025
Q2
$702M Buy
1,804,545
+21,892
+1% +$8.81M 0.12% 146
2025
Q1
$775M Buy
1,782,653
+109,628
+7% +$44M 0.15% 124
2024
Q4
$617M Buy
1,673,025
+61,783
+4% +$25.9M 0.11% 150
2024
Q3
$838M Buy
1,611,242
+17,536
+1% +$9.37M 0.16% 110
2024
Q2
$864M Buy
1,593,706
+28,054
+2% +$14.8M 0.16% 107
2024
Q1
$812M Buy
1,565,652
+36,797
+2% +$18.3M 0.19% 93
2023
Q4
$721M Buy
1,528,855
+50,701
+3% +$23.4M 0.18% 103
2023
Q3
$644M Buy
1,478,154
+7,828
+0.5% +$3.55M 0.18% 98
2023
Q2
$653M Buy
1,470,326
+4,072
+0.3% +$1.88M 0.19% 98
2023
Q1
$674M Buy
1,466,254
+22,212
+2% +$10.6M 0.2% 88
2022
Q4
$741M Buy
1,444,042
+26,167
+2% +$13.3M 0.24% 81
2022
Q3
$644M Buy
1,417,875
+94,270
+7% +$45.1M 0.23% 84
2022
Q2
$639M Sell
1,323,605
-9,439
-0.7% -$4.67M 0.22% 87
2022
Q1
$655M Buy
1,333,044
+38,563
+3% +$17.6M 0.2% 96
2021
Q4
$600M Sell
1,294,481
-6,156
-0.5% -$2.59M 0.18% 104
2021
Q3
$485M Buy
1,300,637
+29,595
+2% +$11.2M 0.16% 117
2021
Q2
$485M Buy
1,271,042
+21,557
+2% +$8.24M 0.16% 114
2021
Q1
$449M Sell
1,249,485
-15,345
-1% -$4.93M 0.16% 113
2020
Q4
$406M Buy
1,264,830
+9,232
+0.7% +$2.83M 0.16% 121
2020
Q3
$337M Sell
1,255,598
-109,644
-8% -$29.5M 0.16% 126
2020
Q2
$359M Sell
1,365,242
-2,670
-0.2% -$712K 0.18% 111
2020
Q1
$311M Buy
1,367,912
+20,848
+2% +$5.68M 0.18% 105
2019
Q4
$407M Buy
1,347,064
+21,316
+2% +$5.87M 0.22% 83
2019
Q3
$318M Buy
1,325,748
+28,939
+2% +$7.93M 0.19% 100
2019
Q2
$366M Buy
1,296,809
+86,892
+7% +$23.7M 0.22% 81
2019
Q1
$347M Buy
1,209,917
+12,361
+1% +$3.57M 0.22% 81
2018
Q4
$315M Buy
1,197,556
+9,327
+0.8% +$2.56M 0.24% 76
2018
Q3
$326M Buy
1,188,229
+28,244
+2% +$7.33M 0.22% 79
2018
Q2
$276M Buy
1,159,985
+12,805
+1% +$2.97M 0.2% 82
2018
Q1
$252M Buy
1,147,180
+54,293
+5% +$12.8M 0.2% 90
2017
Q4
$246M Buy
1,092,887
+44,632
+4% +$9.51M 0.2% 89
2017
Q3
$199M Sell
1,048,255
-5,971
-0.6% -$1.14M 0.17% 106
2017
Q2
$198M Buy
1,054,226
+31,870
+3% +$5.73M 0.19% 99
2017
Q1
$169M Buy
1,022,356
+56,802
+6% +$9.04M 0.17% 111
2016
Q4
$139M Buy
965,554
+41,819
+5% +$5.6M 0.15% 128
2016
Q3
$116M Buy
923,735
+21,689
+2% +$2.8M 0.14% 142
2016
Q2
$118M Buy
902,046
+30,669
+4% +$4.2M 0.15% 130
2016
Q1
$121M Buy
871,377
+21,494
+3% +$2.87M 0.16% 122
2015
Q4
$119M Buy
849,883
+16,371
+2% +$2.26M 0.16% 119
2015
Q3
$117M Sell
833,512
-23,529
-3% -$3.54M 0.17% 114
2015
Q2
$141M Sell
857,041
-4,311
-0.5% -$689K 0.19% 98
2015
Q1
$133M Buy
861,352
+25,010
+3% +$3.56M 0.19% 107
2014
Q4
$105M Buy
836,342
+15,622
+2% +$1.93M 0.16% 134
2014
Q3
$98.2M Sell
820,720
-2,648
-0.3% -$304K 0.16% 127
2014
Q2
$88.6M Sell
823,368
-1,235
-0.1% -$127K 0.15% 138
2014
Q1
$82.1M Sell
824,603
-171,519
-17% -$15.5M 0.15% 140
2013
Q4
$92M Sell
996,122
-141,087
-12% -$12.5M 0.18% 120
2013
Q3
$97.9M Buy
1,137,209
+6,582
+0.6% +$564K 0.2% 107
2013
Q2
$92.3M Buy
+1,130,627
New +$84.6M 0.21% 106

Other funds holding ELV

Charles Schwab's ELV Position: Q2 2026 in Review

Charles Schwab increased its Elevance Health (ELV) stake by 1.9% in Q2 2026, buying an estimated $12.3M and bringing the position to 1,803,703 shares worth $698M. The position accounts for 0.09% of the portfolio, ranked #168.

Charles Schwab first reported a position in ELV in Q2 2013 and has held it in 53 quarters since. The position peaked at $864M in Q2 2024. 1,600 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Charles Schwab held 1,803,703 shares of Elevance Health worth $698M as of Q2 2026.
  • Charles Schwab bought 33,208 Elevance Health shares in Q2 2026, an estimated $12.3M.
  • Elevance Health made up 0.09% of Charles Schwab's portfolio in Q2 2026, its #168 holding.
  • Charles Schwab first reported a position in Elevance Health in Q2 2013 and has held it in 53 quarters since.
  • Charles Schwab's Elevance Health position peaked at $864M in Q2 2024.
  • 1,600 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.